Beyond canonical fusion-driven settings, preclinical work indicates that NGF–TrkA signaling can be pharmacologically suppressed to blunt prometastatic programmes even in fusion-negative osteosarcoma. This evidence concerns the gene NTRK1 and osteosarcoma.